September 03, 2025
On Aug. 11, 2025, Pfizer initiated a recall of Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation due to the potential for damaged bottles during transport. Damage to the bottles may result in leakage, reduced dosing, glass particulate contamination, and physical injury to healthcare providers, posing serious risks such as infection (including sepsis) and embolic events. Octagam is indicated for the treatment of chronic immune thrombocytopenic purpura (ITP) and dermatomyositis (DM) in adults. For full prescribing information, see here.
Last updated: September 03, 2025